ALK and large cell neuroendocrine carcinoma: In the current study, we presented an exceptional case of a young patient with ALK rearrangement-positive LCNEC treated with ALK-TKI, who exhibited concomitant regression of both primary tumor and multiple metastatic lesions after the treatment despite the heterogeneous TIME.